[go: up one dir, main page]

WO1994022829A2 - Dihydropyridines et leurs nouvelles utilisations - Google Patents

Dihydropyridines et leurs nouvelles utilisations Download PDF

Info

Publication number
WO1994022829A2
WO1994022829A2 PCT/US1994/003852 US9403852W WO9422829A2 WO 1994022829 A2 WO1994022829 A2 WO 1994022829A2 US 9403852 W US9403852 W US 9403852W WO 9422829 A2 WO9422829 A2 WO 9422829A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
linear
chain alkyl
branched chain
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/003852
Other languages
English (en)
Other versions
WO1994022829A3 (fr
Inventor
Charles Gluchowski
John M. Wetzel
George Chiu
Mohammad R. Marzabadi
Wai C. Wong
Dhanapalan Nagarathnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Research USA Inc
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Priority to US08/211,764 priority Critical patent/US5767131A/en
Priority to AU64986/94A priority patent/AU6498694A/en
Publication of WO1994022829A2 publication Critical patent/WO1994022829A2/fr
Publication of WO1994022829A3 publication Critical patent/WO1994022829A3/fr
Anticipated expiration legal-status Critical
Priority to US09/972,801 priority patent/US6608086B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Definitions

  • Benign Prostatic Hyperplasia also called Benign Prostatic Hypertrophy
  • Benign Prostatic Hypertrophy is a progressive condition which is characterized by a nodular enlargement of prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, nocturia, a poor urine stream and hesitancy or delay in starting the urine flow.
  • Chronic consequences of BPH can include hypertrophy of bladder smooth muscle, a decompensated bladder and an increased incidence of urinary tract infection.
  • the specific biochemical, histological and pharmacological properties of the prostate adenoma leading to the bladder outlet obstruction are not yet known. However, the development of BPH is considered to be an inescapable phenomenon for the aging male population.
  • BPH is observed in approximately 70% of males over the age of 70.
  • the method of choice for treating BPH is surgery (Lepor, H., Urol. Clinics North Amer., 17, 651 (1990)). Over 400,000 prostatectomies are performed annually (data from 1986).
  • a medicinal alternative to surgery is clearly very desirable.
  • the limitations of surgery for treating BPH include the morbidity rate of an operative procedure in elderly men, persistence or recurrence of obstructive and irritative symptoms, as well as the significant cost of surgery.
  • ⁇ -Adrenergic receptors are specific neuroreceptor proteins located in the peripheral and central nervous systems on tissues throughout the body. These receptors are important switches for controlling many physiological functions and, thus, represent important targets for drug development.
  • ⁇ -adrenergic drugs have been developed over the past 40 years. Examples include clonidine, phenoxybenzamine and prazosin (treatment of hypertension), naphazoline (nasal decongestant), and apraclonidine (treating glaucoma).
  • ⁇ -Adrenergic drugs can be broken down into two distinct classes: agonists (clonidine and naphazoline are agonists), which mimic the receptor activation properties of the endogenous neurotransmitter norepinephrine, and antagonists (phenoxybenzamine and prazosin are antagonists), which act to block the effects of norepinephrine.
  • This invention relates to uses for dihydropyridine derivatives previously reported in Flockerzi, D., et. al., US Patent 4,707,486, issued November 17, 1987, and Zimmerman, P., et.al., PCT International Patent Applic- ation WO 91/09846, published July 11, 1991, including methods of treatment of BPH.
  • This invention also relates to novel dihydropyridine derivatives.
  • This invention further relates to potent and selective alpha 1C antagonists without significant calcium channel activity.
  • Figure 1 illustrates condensation to form dihydro- pyridines by Reaction Scheme 1 (Method A).
  • Figure 2 illustrates condensation to form dihydro- pyridines by Reaction Scheme 2 (Method B).
  • Figure 3 illustrates condensation to form dihydro- pyridines by Reaction Scheme 3 (Method C).
  • Figure 4 illustrates condensation to form dihydro- pyridines by Reaction Scheme 4 (Method D).
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR', OCOR' , OCOOR', OCONHR' , NH 2/ NHR', NR , 2 , NHCOR' , NHCOOR' or NHCONHR' , where R' is a linear or branched chain alkyl group.
  • the invention still further provides a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR"', OCOR” ' , OCOOR”', OCONHR"', NH 2 , NHR"', NR'" 2 , NHCOR'", NHCOOR'" or NHCONHR'", where R"' is a linear or branched chain alkyl group.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , Where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention further provides a compound having the structure:
  • NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R" ' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is H,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • n is 2, 3 or 4.
  • a general objective of the invention is to provide a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR"', NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR'", NHCONHR'", where R"' is a linear or branched chain alkyl group.
  • the present invention provides a compound useful for the treatment of benign prostatic hyperplasia and other disorders having the structure:
  • R' is a methyl, ethyl, or propyl group; wherein j is 1 or 2; wherein p is 0, 1, or 2; wherein R 4 is H, or a linear or branched chain, or cyclic alkyl group; wherein R 5 and R 6 are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group, or together constitute a methylene- dioxy group; and wherein R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR", OCOR", NH 2 , NHR", NR" 2 , or NHCOR", where R" is a linear chain alkyl group,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR"', OCOOR”', OCONHR'", NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR”', NHCONHR'", where R"' is a linear or branched chain alkyl group.
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR', OCOR', OCOOR', OCONHR', NH 2 , NHR', NR' 2 , NHCOR', NHCOOR' or NHCONHR', where R' is a linear or branched chain alkyl group.
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR", OCOR", OCOOR", OCONHR", NH 2 , NHR", NR" 2 , NHCOR", NHCOOR” or NHCONHR", where R" is a linear or branched chain alkyl group.
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR"', NH 2 , NHR'", NR"' 2 , NHCOR'", NHCOOR”' or NHCONHR'", where R"' is a linear or branched chain alkyl group.
  • the invention still further provides a method of treating diseases mediated by ⁇ , receptors in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure:
  • OCOR NH 2 , NHR '' , NR" 2 or NHCOR
  • R is a linear chain alkyl group, a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR'", OCOR'", OCOOR”', OCONHR'", NH 2 , NHR'", NR'" 2 , NHCOR'", NHCOOR' " or NHCONHR'", where R'" is a linear or branched chain alkyl group.
  • the invention provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5.
  • the term "pharmaceutically acceptable counterion” shall refer to any anion present in or compatible with mammalian tissue physiology, and includes among others chloride, bromide, iodide, acetate, carbonate, bicarbonate, tartrate, citrate, ascorbate, succinate, maleate, lactate, phosphate, sulfate, hydrogen phosphate, hydrogen sulfate or benzoate.
  • the invention provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4
  • the invention provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , Where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , 0COOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention also provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, wherein
  • R is a methyl, ethyl or propyl group; wherein Y is -
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • a and X are independently the same or different and are CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention further provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, F, OH, OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R iv is a linear or branched chain alkyl group.
  • the invention provides a compound having the structure:
  • X is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention further provides a compound having the structure:
  • Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR"OH, NR''OH'” or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalky
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv br NHCONHR iv , Where R' is a linear or- branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • R' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R,'Z-, NHCOR', N 3 , NO 2 , or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an alkenyl or alkynyl group, or an
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4
  • the invention provides a compound having the structure:
  • Q is OH, OR'', SH, SR'", NH 2 , NHR ''', NR 2 ' ' ' ,
  • R' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 , or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention provides a compound having the structure:
  • R" is H, a linear or bfanched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5.
  • the invention still further provides a compound having the structure:
  • NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 t
  • NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
  • the invention provides a compound having the structure:
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
  • the invention provides a compound having the structure:
  • Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR''OH, NR' 'OR'” or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxy
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5 ; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
  • the invention provides a compound having the structure:
  • Q is OH, OR", SH, SR"', NH 2 , NHR ''', NR 2 ''',
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'
  • OCOR' NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR' , CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein i is 1 or 2; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 "',
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R''' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t w, where w is NH 2 ,
  • NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W, where W is
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • n is 2, 3 or 4.
  • the invention provides a compound having the structure:
  • NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) f W, where W
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and
  • n 2, 3 or 4.
  • the invention provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • the invention provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
  • R' is a linear or branched chain alkyl group, or an aryl group; wherein R is H, a linear or branched chain alkyl or acyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH,N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) V W > , or a linear or branched chain alkyl group, or an arylalkyl group, or an alken
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R" ' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R" ' is a linear or branched chain alkyl group, or an aryl group
  • R is H, a linear or branched chain alkyl or acyl group, or an aryl group
  • X is H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group; wherein R is H or H or
  • the invention provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
  • R' is a linear or branched chain alkyl group, or an aryl group
  • X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl
  • the invention provides a compound having the structure:
  • NR''OH, NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group
  • X and Y are independently the same or different and are H, OH, Cl, Br, I, F, NO 2 , CN, NH 2 , or CF 3 , or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfoxide, or mono- or dialkylamino group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryj group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ),W,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5
  • R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
  • n is 0, 1, 2, 3 or 4.
  • the invention provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
  • R' is a linear or branched chain alkyl group, or an aryl group; wherein R is H or a linear or branched chain alkyl or acyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) V W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5
  • R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R' is a linear or branched chain alkyl group, or an aryl group
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • COO(CH 2 ) q OR' or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl,
  • quinolinyl isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5
  • R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
  • m and n are independently the same or different and are 0 or 1
  • p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 11 is H or a linear chain alkyl group
  • R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group
  • wherein j is 1, 2, 3 or 4
  • n 2, 3 or 4.
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R''' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2 , 3 or 4.
  • the invention also provides a compound having the structure:
  • R 0 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is O, S or NH, where W 1 is NH 2 , NHR', NR 2 ', NHOH,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group
  • q is 2, 3, 4 or 5
  • R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • X is NH, NR", O, or S, where R" is H or a linear or branched chain alkyl or acyl group, or an aryl group; wherein Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N +
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 2, 3 or 4.
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group
  • R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N +
  • the invention also provides a compound having the structure
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R' an d R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl grpup
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 , R 1 and R' are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv ,
  • R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • A is CH 2 , CR ⁇ 2 , NH, NR ⁇ , NCHO, NCOR ⁇ , NOH, O or S, where R ⁇ is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl or acyl group
  • p is 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl or acyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'" is a linear or branched chain alkyl group, or an aryl group; wherein R 0 , and R 1 are independently the.
  • H a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is 0, S or NH, where W 1 is NH 2 , NHR', NR 2 ', NHOH, N + R
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group; wherein R is H or a linear or branched chain alkyl or acyl group.
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group, where W 0 is 0, S or NH, where W 1 is NH 2
  • the invention still further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R is H or a linear or branched chain alkyl or acyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , N
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ' , NHOH, N + R 3
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • R' is a linear or branched chain alkyl group, or an aryl group, where Z- is a pharmaceutically acceptable counterion, and t is 1, 2, 3, 4, 5 or 6 and v is 2, 3, 4, 5 or 6; wherein R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR' , CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinoliny
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • CHO, COR', COSH, COSR', COO(CH 2 ),OH or COO(CH 2 ) q OR' or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquin olinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • B is CH or N; wherein Q is OH, OR", SH, SR"',
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 NR''OH, NR''OH”', or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • B is CH or N; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 "', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxy- alkyl, or an aryl
  • Z- is a pharmaceutically acceptable counterion, and t is 1, 2, 3, 4, 5 or 6 and v is 2, 3, 4, 5 or 6; wherein R 7 is an aryl or diarylalkyl group; wherein R 11 is a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j and k are independently the same or different and are 0, 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • B is CH or N; wherein Q is OH, OR" , SH, SR' " ,
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an al
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • B is CH or N; wherein Q is OH, OR", SH, SR'", NH 2/ NHR'", NHR''', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' ' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R" ' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an ary
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and n is 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N,, OR iv , OCOR iv , OCOOR iv ,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • m and n are independently the same or different and are 0 or 1
  • p is 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • B is O or S; wherein Q is OH, OR", SH, SR"',
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR, NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • B is O or S; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ' " , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'" is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an ary
  • the invention further provides a compound having the structure:
  • B is O or S; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • B is O or S; wherein Q is OH, OR", SH, SR"',
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR'", NR 2 ' “ , NR'OH, NR''OR'”, or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; and wherein n is 0, 1, 2, 3 or 4.
  • B is O or S; wherein Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl or an aryl group, or (CH 2 ) t W
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR", NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • B is O or S; wherein X is NH, NR', O, or S, wherein
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • CF 3 OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR', CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO(CH 2 ) q OR', or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • m and n are independently the same or different and are 0 or 1
  • p is 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • B is O, S or NR 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ' " , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; and n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • B is O, S or N 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR"', NR 2 ' " , NR'OH, NR'OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R'” is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or
  • B is O, S or N 12 ; wherein Q is OH, OR", SH, SR'", NH 2 , NHR'", NR 2 ''', NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R" ' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 11 is H or a linear chain alkyl group
  • R 12 is H or a linear chain alkyl group
  • n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • B is CH or N; wherein Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 '" , NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R' " is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azido- alkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl or acyl group; wherein j is 1, 2, 3 or 4; and n is 0, 1, 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or.5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • p is 0, 1, 2 or 3.
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • B is 0, S or NR' , where R' is H or a linear chain alkyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • B is O, S or NR', where R' is H or a linear chain alkyl group
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group
  • m and n are independently the same or different and are 0 or 1
  • p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R'' is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3
  • Q is OH, OR", SH, SR"', NH 2 , NHR''', NR 2 ''' ,
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
  • R' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is N H2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 0, 1, 2, 3 or 4.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • R 7 and R 8 are independently the same or different and are H, CN, CF 3 , OH, OR', OCOR', NH 2 , NHR', NR' 2 , NHCOR', CONH 2 , CONHR', CONR 2 ', COOH, COOR', CHO, COR', COSH, COSR', COO(CH 2 ) q OH or COO (CH 2 ) q OR' , or a benzyl group, a linear or branched chain alkyl or cycloalkyl group, or are a heteroaryl group comprising a pyridyl, indolyl, indolylalkyl, quinolinyl, isoquinolinyl, pyrryl, furyl or thiophene group, or an aryl group having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • R' is a linear or branched chain alkyl group, or an aryl group; wherein R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein n is 2, 3 or 4.
  • the invention still further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; and wherein n is 0, 1, 2, 3 or 4.
  • the invention provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein n is 2, 3 or 4; and wherein p is 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; and wherein p is 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 and R 13 are independently the same or different and are H or a linear chain alkyl group; wherein m and n are independently the same or different and are 0 or 1; and wherein p is 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 '
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 11 is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein n is 2, 3 or 4; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • Q is OH, OR", SH, SR'", NH 2 , NHR"', NR 2 ' '',
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl.
  • R' ' ' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3 , NO 2 or CH 2 W 0 (CH 2 ) v W 1 , or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R' is a linear or branched chain alkyl group, or an aryl
  • the invention further provides a compound having the structure:
  • NR''OH, NR''OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 1 is H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR', N 3
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R" is H or a linear chain alkyl group; wherein R 12 is H or a linear chain alkyl group; wherein n is 2, 3 or 4; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention still further provides a compound having the structure:
  • Q is OH, OR", SH, SR"', NH 2 , NHR'", NR 2 ' ' ' ,
  • NR''OH, NR'OR' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 11 is H or a linear chain alkyl group
  • R 12 is H or a linear chain alkyl group
  • j is 1, 2, 3 or 4
  • n is 0, 1, 2, 3 or 4
  • s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • Q is OH, OR', SH, SR'', NH 2 , NHR '', NR'OH, NR'OR'' where R' is H, or a linear or branched chain alkyl, trialkylsilylalkyl, or cyanoalkyl group, or an aryl group, and where R" is a linear or branched chain alkyl group, or an aryl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention further provides a compound having the structure:
  • X is NH, NR, O or S, where R is H or a linear or branched chain alkyl or acyl group, or an aryl group;
  • Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5; -(CH 2 ) h -O-(CH 2 ) k -, where h and k are independently the same or different and are 2, 3 or 4;
  • -(CH 2 ) B -CH CH-(CH 2 ) k -; or -(CH 2 ) h -C ⁇ C- (CH 2 ) k -, where h and k are independently the same or different and are 1, 2, 3 or 4;
  • Z is O, NH, NCHO, NCOR', NR', NOR' or CH 2 , where R' is a methyl, ethyl or propyl group; wherein R 1 is H, Cl, Br, I, F, NO 2 , CN,
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv ,
  • R' is a linear or branched chain alkyl group
  • R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5
  • R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • A is CH 2 , CR 2 , NH, NR, NCHO, NCOR, NOH, O or S, where R is a methyl, ethyl or propyl group;
  • X is NH, NR' , O or S, where R' is H or a linear or branched chain alkyl or acyl group, or an aryl group;
  • Y is -(CH 2 ) n -, where n is 1, 2, 3, 4 or 5; -(CH 2 ) h -O-(CH 2 ) k -, where h and k are independently the same or different and are 2, 3 or 4;
  • -(CH 2 ) h -CH CH-(CH 2 ) k -; or -(CH 2 ) h -C ⁇ C-(CH 2 ) k -, where h and k are independently the same or different and are 1, 2, 3 or 4;
  • Z is O, NH, NCHO, NCOR",
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention also provides a compound having the structure:
  • X is NH, NR, O or S, where R is H or a linear or branched chain alkyl or acyl group, or an aryl group;
  • R 9 and R 10 are independently the same or different and are H, Cl, Br, I, F, OH, NO 2 , N 3 , OR iv , OCOR iv , OCOOR iv , OCONHR iv , NH 2 , NHR iv , NR iv 2 , NHCOR iv , NHCOOR iv or NHCONHR iv , where R' is a linear or branched chain alkyl group, and R iv is a linear or branched chain alkyl group, and q is 2, 3, 4 or 5; wherein R 12 is H or a linear chain alkyl group; wherein j is 1, 2, 3 or 4; wherein m and n are independently the same or different and are 0 or 1; wherein p is 0, 1, 2 or 3; and wherein s and t are independently the same or different and are 0, 1, 2 or 3.
  • the invention provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention additionally provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • NR''OH"' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group
  • R'" is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHC
  • n 2 , 3 or 4.
  • the invention provides a compound having the structure:
  • Q is OH, OR'', SH, SR''', NH 2 ' NHR' NR 2 '", NR''OH, NR''OR'", or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group, where R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl, or an aryl group, and R"' is a linear or branched chain alkyl group, or an aryl group; wherein R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 )
  • NR''OH' or a linear or branched chain alkyl group, or an arylalkyl group, or an alkenyl or alkynyl group, or an aryl group
  • R" is H, a linear or branched chain alkyl group, trialkylsilylalkyl, cyanoalkyl or an aryl group
  • R"' is a linear or branched chain alkyl group, or an aryl group
  • R 0 and R 1 are independently the same or different and are H, a linear or branched chain alkyl, an alkoxyalkyl, azidoalkyl, aminoalkoxyalkyl, azidoalkoxyalkyl, trihaloalkoxyalkyl, aminoalkyl, hydroxyalkyl, or an aryl group, or (CH 2 ) t W, Where W is NH 2 , NHR', NR 2 ', NHOH, N + R 3 'Z-, NHCOR'
  • the invention provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention still further provides the (+) and (-) enantiomer of the compound having the structure:
  • the invention also provides a compound of having the structure:
  • the invention additionally provides the (+) and (-) enantiomer of the compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention provides a compound having the structure:
  • the invention also provides a compound having the structure
  • the invention additionally provides a compound having the structure:
  • the invention provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention provides a compound having the structure:
  • the invention further provides a compound having the structure :
  • the invention also provides a compound having The structure:
  • the inven tion further provides a compound having the structure
  • the invention still further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention still further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention still further provides a compound having the structure:
  • the invention further provides a compound having the structure:
  • the invention also provides a compound having the structure:
  • the invention additionally provides a pharmaceutical composition which comprises the compound disclosed herein in a therapeutically effective amount and a pharmaceutically acceptable carrier.
  • the invention includes the pharmaceutical composition wherein the carrier is a solid and the composition is a tablet.
  • the therapeutically effective amount is an amount from about 0.1 to about 500 mg. In certain embodiments, the therapeutically effective amount is from about 1 to 60 mg.
  • the invention also includes a pharmaceutical composition wherein the carrier is a liquid and the composition is a solution, wherein the therapeutically effective amount is an amount from about 0.1 to about 500 mg per mL of solution and in certain embodiments, the therapeutically effective amount is an amount from about 1 to about 60 mg per mL of solution.
  • the invention further provides a pharmaceutical composition wherein the carrier is a gel and the composition is a suppository, wherein the therapeutically effective amount is an amount from about 0.1 to about 500 mg.
  • the invention also encompasses a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
  • the invention provides a method of lowering intraocular pressure in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
  • the invention further provides a method of inhibiting cholesterol synthesis in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
  • the invention has general utility in providing a method of treating diseases mediated by a. receptors in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds disclosed herein.
  • the invention additionally provides a method of treating diseases mediated by ⁇ 1 receptors in a subject which comprises administering to the subject a therapeutically effective amount of any one of the compounds of the preferred embodiments.
  • the dihydropyridine derivatives disclosed herein are potent, selective alpha-1 c antagonists with weak calcium channel antagonist activity, and, it is anticipated, will be useful in providing a novel treatment for benign prostatic hyperplasia. This therapeutic use is supported by data presented in Tables 2 and 3 hereinbelow, which illustrate the beneficial effects of representative examples of these compounds in well established models of prostate contraction.
  • the compounds disclosed herein may also be useful as cardiovascular antihypertensive agents, as inhibitors of cholesterol synthesis, and as agents for decreasing intraocular pressure in a mammalian eye, as well as for treating male erectile dysfunction, congestive heart failure, Raynaud's disease, and multidrug resistance.
  • the present invention therefore provides a method of treating benign prostatic hyperplasia, a method of reducing cardiovascular hypertension, cholesterol synthesis, and intraocular pressure in a mammalian eye, a method for treating male erectile dysfunction, congestive heart failure, Raynaud's disease, and multidrug resistance.
  • the method of treating benign prostatic hyperplasia comprises administering a quantity of any of the claimed dihydro- pyridines effective to treat benign prostatic hyperplasia.
  • the drug may be administered to a patient afflicted with benign prostatic hyperplasia by any conventional route of administration, including, but not limited to, intravenous, intramuscular, oral, subcutaneous, intratumoral, intradermal, and parenteral.
  • the effective quantity is between 0.001 mg and 10.0 mg per kg of subject body weight.
  • the present invention also provides compounds useful for preparing a pharmaceutical composition comprising any of the claimed dihydropyridines disclosed herein and a pharmaceutically acceptable carrier.
  • the composition may contain between 0.1 mg and 500 mg of the claimed compound, and may be constituted in any form suitable for the mode of administration selected.
  • Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixers, and suspensions.
  • Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
  • the drug may otherwise be prepared as a sterile solid composition which may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectible medium.
  • Carriers are intended to include necessary and inert binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
  • Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular dihydropyridine in use, the strength of the preparation, the mode of administration, and the advancement of the disease condition. Additional factors depending on the particular patient being treated will result in a need to adjust dosages, including patient age, weight, gender, diet, and time of administration.
  • the following Experimental Details are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims which follow thereafter.
  • Example 1 is illustrative of Method A, which is outlined in Reaction Scheme 1.
  • EXAMPLE 1 is illustrative of Method A, which is outlined in Reaction Scheme 1.
  • N-(3-(4,4-Diphenylpiperidin-1-yl)propyl)acetoacetaaide Diketene (0.44 mL, 5.7 mmol, 1.3 equiv, Aldrich) was added at room temperature to a stirred solution of 1-(3- aminopropyl)-4, 4-diphenylpiperidine (1.288 g, 4.37 mmol, 1.0 equiv) in anhydrous toluene (15 mL) under argon, and stirring was continued for 48 hours. The mixture was concentrated to give 1.294 g (78%) of white solid, which was used for the next reaction without purification.
  • N-(3-(4,4-diphenylpiperid in-1-yl)propyl) acetoacetamide (229 mg, 0.61 mmol) was mixed with methyl 3-aminocrotonate (70 mg, 0.61 mmol) and p-trifluoromethylbenzaldehyde (83 ul, d 1.275, 0.61 mmol) in 2-propanol (5 mL). The mixture was heated at reflux for 3 days. The precipitate which formed upon cooling to room temperature was filtered off to give a pale yellow solid (160 mg). Recrystallization from 2-propanol afforded white crystals (117 mg, 31% yield) : mp 228-231°C. Anal. Calcd. for C 37 H 40 F 3 N 3 O 3 : C, 70.35; H, 6.38; N, 6.65. Found: C, 70.26; H,6.40; N,6.51.
  • Example 2 is illustrative of Method B, which is outlined in Reaction Scheme 2.
  • (+) and (-)-2 The enantiomers of 2 were separated on a chiral HPLC column as follows. Four injections of the racemate (16 mg per injection in 2 ml Of EtOH) were made onto a Chiralpak AS column (20 x 250 mm, Daicel), which was eluted with EtOH-hexane-diethylamine (10:90:0.05) at a flowrate of 9.0 ml/min with UV detection at 300 nm. The retention times for the two enantiomers were 50 ((+)- isomer) and 65 ((-)-isomer) min repectively. The desired compounds were collected and precipitated from Et 2 O/CH 2 Cl 2 to give yellowish powders.
  • Example 3 is illustrative of Method C, which is outlined in Reaction Scheme 3.
  • the crude product was charged with 250 mL of methanol and 1.10 g of 10% Pd/C, and the mixture was hydrogenated using the balloon method for 24 h.
  • the reaction mixture was filtered through celite 545, concentrated in vacuo, partitioned between water (200 mL, containing 3.0 g of NaOH) and ethyl acetate (100 mL).
  • the separated oil was extracted with 2 X 200 mL of ethyl acetate, and 2 X 200 mL of dichloromethane.
  • Example 4 is illustrative of Method D, which is outlined in Reaction Scheme 4.
  • EXAMPLE 4 2-Cyanoethyl 3-Oxopentanoate.
  • a mixture of 4.86 g of ethyl propionylacetate (33.7 mmol) and 2.00 g of 3- hydroxypropionitrile (28.1 mmol) were placed in a round bottom flask (magnetically stirred) equipped with a short distillation path. The resulting mixture was gradually heated to 180-205°C in an oil bath. The distillate was collected (1.2 mL). The mixture was then cooled to room temperature and the residue was distilled under reduced pressure to give 2.64 g of product: bp 95-98°C (0.5 mm Hg). The product was used in the next step after spectral characterization.
  • Method A A stirred solution of 191 mg of 1-(3-aminopropyl)- 4,4-diphenylpiperidine (0.676 mmol), 123 mg of ethyl 3- oxo-3-(furan-3-yl)propionate (0.676 mmol), and 83 mg of dimethylaminopyridine (0.676 mmol) in 5 mL of dry toluene were heated at reflux temperature for 18 hrs, cooled, and the residue was dissolved in 30 mL of EtOAc The resulting solution was extracted with 2 X 20 mL of aqueous 1 N HCl solution.
  • Method B A mixture of 894 mg of ethyl 3-(furan-3-yl)-3- oxopropionate (4.90 mmol) and 347 mg of 3- hydroxypropionitrile (4.88 mmol) was heated in an oil bath to 180-20°5C for 0.5 hrs. The reaction mixture was cooled and distilled under reduced pressure. Three fractions were obtained. 1 H NMR indicated that the third fraction (bp 100-14°0C (0.5 mm Hg)) was a 1:1 mixture of ethyl 3-(furan-3-yl)-3-oxopropionate and 2-cyanoethyl 3- (furan-3-yl)-3-oxopropionate. This mixture was used in the condensation step after spectral characterization.
  • EXAMPLE 44 ⁇ oetoaoetie acid 3-(N,N-dimethyl)aminopropyl ester.
  • Diketene (2.54 mL, 33.0 mmol, 1.30 equiv) was added to a solution of 3-(N,N-dimethyl)aminopropan-1-ol (3.00 mL, 25.4 mmol, 1.00 equiv, Aldrich) in toluene (30 mL) and the mixture was stirred at room temperature for 70 hours. The solvent was removed to afford 4.76 g of brown oil, which was characterized spectroscopically and used for the next reaction without purification.
  • EXAMPLE 50 3-(Piperidin-1-yl)propyl acetoacetate.
  • Diketene (1.48 mL, 19.2 mmol, 1.30 equiv) was added to a solution of 1- (3-hydroxypropyl)piperidine (2.12 g, 14.8 mmol, 1.00 equiv, Leonard, N. J. ; Musker, W. K. J. Am. Chem. Soc. 1960, 82 , 5148) in toluene (30 mL), and the mixture was stirred under argon for 72 hours at room temperature. Removal of solvent gave 3.52 g (100%) of light brown, viscous oil, which was characterized spectroscopically and used for the next reaction without purification.
  • N-(3-(Piperidin-1- yl)propyl) acetoacetamide (4.53 g, 20.0 mmol, 1.00 equiv), methyl 3-aminocrotonate (2.37 g, 20.0 mmol, 1.00 equiv) and 4-nitrobenzaldehyde (3.02 g, 20.0 mmol, 1.00 equiv) were stirred together in 2-propanol (60 mL) at reflux for 60 hours under argon. After removal of the solvent, the residue was purified by flash chromatography (SiO 2 , MeOH- EtOAc 0:1 to 1:6) to afford 2.25 g of yellow solid.
  • EXAMPLE 52 (4,4-Diphenylpiperidin-1-yl)acetonitrile.
  • N-(2-(4,4- Diphenylpiperidin-1-yl) ethyl) acetoacetamide (2.34 g, 6.41 mmol, 1.00 equiv), methyl 3-aminocrotonate (0.839 g, 7.06 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.07 g, 7.06 mmol, 1.10 equiv) were stirred together in 2-propanol (40 mL) at reflux for 68 hours under argon.
  • N-(4-(4,4- Diphenylpiperidin-1-yl) butyl) acetoacetamide (2.86 g, 7.30 mmol, 1.00 equiv), methyl 3-aminocrotonate (0.953 g, 8.03 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.21 g, 8.03 mmol, 1.10 equiv) were stirred together in 2-propanol (50 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified by flash chromatography (SiO 2 , MeOH-EtOAc 0:1 to 1:9) to afford 1.40 g (31%) of yellow solid, which was characterized spectroscopically.
  • N-(2-(4,4- Diphenylpiperidin-1-yl) ethyl) acetoacetamide (2.34 g, 6.41 mmol, 1.00 equiv), 3-aminocrotonamide (0.706 g, 7.05 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.07 g, 7.05 mmol, 1.10 equiv) were stirred together in 2-propanol (40 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 0:1 to 1:5; 2.
  • N-(4-(4,4- Diphenylpiperidin-1-yl)butyl)acetoacetamide (2.86 g, 7.30 mmol, 1.00 equiv), 3-aminocrotonamide (0.804 g, 8.03 mmol, 1.10 equiv) and 4-nitrobenzaldehyde (1.21 g, 8.03 mmol, 1.10 equiv) were stirred together in 2-propanol (50 mL) at reflux for 72 hours under argon. After removal of the solvent, the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 1:4; 2.
  • N-(3-(4- Phenylpiperidin-1-yl)propyl)acetoacetamide (1.60 g, 5.30 mmol, 1.00 equiv)
  • N-methyl-3-aminocrotonamide 690 mg, 6.10 mmol, 1.15 equiv
  • 4-nitrobenzaldehyde 920 mg, 6.10 mmol, 1.15 equiv
  • 2- propanol 50 mL
  • the residue was purified twice by flash chromatography on SiO 2 (1. MeOH-EtOAc 1:5; 2. CHCl 3 -NH 3 in MeOH (0.67 M) 100:15).
  • N-[3- (1,2,3, 4-Tetrahydroisoquinolin-2- yl)propyl]acetoacetamide A suspension of N-(3- bromopropyl)acetoacetamide (4.50 g, 20.3 mmol, 1.00 equiv), 1,2,3,4-tetrahydroisoquinoline (3.30 mL, 26.3 mmol, 1.30 equiv), K 2 CO 3 (3.64 g, 26.3 mmol, 1.30 equiv), and Kl (330 mg, 1.99 mmol, 0.10 equiv) in acetone (60 mL) was stirred at reflux for 14 hours. The mixture was cooled to room temperature, filtered, and concentrated.
  • EXAMPLE 64 4-Dihydro-6-methyl-4- (4-nitrophenyl) -5- ⁇ H-[3- (4,4- d iphenylpiperid in- 1 -yl ) propyl ] ⁇ carboxamido- [2,3,d]uracilylpyridine (64) .
  • This compound was prepared according to Method B.
  • This compound was prepared according Method B from 86.8 mg of 2-(furan-3-yl)-1,4-dihydro-3-(imidazol-1- yl)carbonyl-5-methoxycarbonyl-6-methyl-4-(4- nitro)phenylpyridine (0.200 mmol) and 65.5 mg of 1-(3- aminopropyl) -4-phenylpiperidine (0.300 mmol) in 3 mL of dry THF.
  • This compound was prepared according to Method B from 51.1 mg of 5-carboxamido-2- (furan-3-yl)-1,4-dihydro-3-(imidazol-1-yl)carbonyl-6- methyl-4-(4-nitro) pheny lpyridine (0.118 mmol) and 38.3 mg of 2-(3-aminopropyl)-1,2,3,4-tetrahydro-6,7- dimethoxyisoquinoline (0.153 mmol) in 3 mL of dry THF. The crude product was chromatographed on 100 g of silica (gradient elution: 5% to 15% MeOH-EtOAc) to give the free base as a yellow foamy solid (71%).
  • EXAMPLE 68 2-Cyanoethyl 3-Oxohexanoate.
  • a mixture of ethyl 3- oxohexanoate (33.7 mmol) and 3-hydroxypropionitrile (28.1 mmol) were placed in a round bottom flask (magnetically stirred) equipped with a short distillation path. The resulting mixture was gradually heated to 180-205°C in an oil bath. The distillate was collected. The mixture was then cooled to room temperature and the residue was distilled under reduced pressure to give 2-cyanoethyl 3- oxohexanoate.
  • the maroon solution was concentrated to a small volume under reduced pressure, partitioned between 50 mL of water and 50 mL of ethyl acetate, separated, and the aqueous solution was washed with 2 X 20 mL of ethyl acetate.
  • the combined organic extracts were dried (MgSO 4 ), and the solvent was removed in vacuo to give the desired product as a foamy yellow solid.
  • the acid was used in the next step without further purification.
  • the solvent was removed in vacuo and the crude product is chromatographed on 50 g of silica packed with 5% MeOH-EtOAc. The column was eluted with MeOH-EtOAc to afford the title compound as a yellow foamy solid.
  • To this product was added HCl in ether (1 M) in a minimum amount of ethyl acetate. The precipitate was collected, washed with ether (2 X 5 mL), and dried to give the hydrochloride salt as a yellow powder, which was characterized spectroscopically.
  • the fumarate salt was prepared by mixing fumaric acid (8.7 mg, 0.0749 mmol) and the free base (0.0749 mmol) in 2 mL of 1:1 acetone-water. The product was purified by recrystallization.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthode de traitement de l'hyperplasie prostatique bénigne par administration d'une dose à effet thérapeutique d'un composé de structure (I), où Y représente -(CH2)n- où n est égal à 1, 2, 3, 4 ou 5; -(CH2)h-O-(CH2)k, où h et k sont indépendamment identiques ou différents et égaux à 2, 3 ou 4; -(CH2)h-CH=CH-(CH2)k; ou -(CH2)h-C C-(CH2)k- où h et k sont indépendamment identiques ou différents et égaux à 1, 2, 3, ou 4; où Z représente O, NH ou CH2; où R1 représente un groupe alkyle, alcoxyalkyle ou arylalkyle linéaire ou à chaîne ramifiée; où R2 et R4 sont indépendamment identiques ou différents et représentent H ou un groupe alkyle linéaire ou à chaîne ramifiée; où R3 représente H, un groupe alkyle, alcoxy, alcoxyalkyle ou acyle linéaire ou à chaîne ramifiée; où R5 et R6 sont indépendamment identiques ou différents et représentent H, OH, Cl, Br, F, HO¿2?, CN, CF3 ou NH2, ou un groupe alkyle, alcoxy, alcoxycarbonyle, acyle, alkylsulfoxyde, alkylsulfone linéaire ou à chaîne ramifiée, ou un groupe mono ou dialkylamino. D'autres composés actifs à un, deux, ou trois cycles sont également présentés ainsi que des préparations pharmaceutiques les contenant et leurs procédés d'utilisation dans le traitement de l'HPB, l'inhibition de la synthèse du cholestérol, et la réduction de la pression intraoculaire.
PCT/US1994/003852 1993-04-05 1994-04-05 Dihydropyridines et leurs nouvelles utilisations Ceased WO1994022829A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08/211,764 US5767131A (en) 1993-04-05 1994-04-05 Dihydropyridines and new uses thereof
AU64986/94A AU6498694A (en) 1993-04-05 1994-04-05 Dihydropyridines and new uses thereof
US09/972,801 US6608086B2 (en) 1993-04-05 2001-10-05 Dihydropyridines and new uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4321293A 1993-04-05 1993-04-05
US08/043,212 1993-04-05
US12016993A 1993-09-10 1993-09-10
US08/120,169 1993-09-10
US16630893A 1993-12-10 1993-12-10
US08/166,308 1993-12-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16636793A Continuation-In-Part 1993-04-05 1993-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/211,764 A-371-Of-International US5767131A (en) 1993-04-05 1994-04-05 Dihydropyridines and new uses thereof
US09/098,699 Division US6211198B1 (en) 1993-04-05 1998-06-15 Dihydropyridines and new uses thereof

Publications (2)

Publication Number Publication Date
WO1994022829A2 true WO1994022829A2 (fr) 1994-10-13
WO1994022829A3 WO1994022829A3 (fr) 1995-01-05

Family

ID=27366299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003852 Ceased WO1994022829A2 (fr) 1993-04-05 1994-04-05 Dihydropyridines et leurs nouvelles utilisations

Country Status (3)

Country Link
AU (1) AU6498694A (fr)
IL (1) IL109220A0 (fr)
WO (1) WO1994022829A2 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620993A (en) * 1995-06-07 1997-04-15 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
EP0790826A4 (fr) * 1994-11-16 1998-11-11 Synaptic Pharma Corp Dihydropyrimidines et leurs utilisations
WO1999032446A1 (fr) * 1997-12-22 1999-07-01 Ajinomoto Co., Inc. Agent de conservation de fraicheur pour fleurs coupees
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6232318B1 (en) 1998-11-12 2001-05-15 Merck & Co., Ltd. Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists
US6235759B1 (en) 1998-10-29 2001-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6316437B1 (en) 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6326372B1 (en) 1999-09-30 2001-12-04 Merck & Co., Inc. Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6387893B1 (en) 1999-09-30 2002-05-14 Merck & Co., Inc. Spirotricyclic substituted azacycloalkane derivatives and uses thereof
US6436962B1 (en) 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
DE19754322B4 (de) * 1997-12-08 2006-01-26 Degussa Ag Verfahren zur Herstellung von Salzen cyclischer Amidine
US7247645B2 (en) 1999-06-23 2007-07-24 Ajinomoto Co., Inc. Dihydropyridine derivatives
WO2008052431A1 (fr) * 2006-10-25 2008-05-08 Beijing Huaanfo Biomedical Research Centre. Inc Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
US7618959B2 (en) 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN109721596A (zh) * 2017-10-27 2019-05-07 广东东阳光药业有限公司 苯基取代的二氢吡啶类化合物及其用途
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4755512A (en) * 1984-04-11 1988-07-05 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
US4895846A (en) * 1984-04-11 1990-01-23 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moieties
EP0176956B1 (fr) * 1984-09-28 1994-06-15 Byk Gulden Lomberg Chemische Fabrik GmbH Composés diaryliques
JPS61227567A (ja) * 1985-04-01 1986-10-09 Eisai Co Ltd １，４−ジヒドロピリジン誘導体
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
JPH0688973B2 (ja) * 1987-03-12 1994-11-09 京都薬品工業株式会社 １，４−ジヒドロピリジン誘導体
WO1991009846A1 (fr) * 1989-12-22 1991-07-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelles dihydropyridines
US5166148A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 2-amino-1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP0790826A4 (fr) * 1994-11-16 1998-11-11 Synaptic Pharma Corp Dihydropyrimidines et leurs utilisations
US5942517A (en) * 1994-11-16 1999-08-24 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6727257B1 (en) 1994-11-16 2004-04-27 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6248747B1 (en) 1994-11-16 2001-06-19 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US5620993A (en) * 1995-06-07 1997-04-15 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
US5977115A (en) * 1995-06-07 1999-11-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6274583B1 (en) 1995-06-07 2001-08-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6075038A (en) * 1995-06-07 2000-06-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6255315B1 (en) 1997-06-18 2001-07-03 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
DE19754322B4 (de) * 1997-12-08 2006-01-26 Degussa Ag Verfahren zur Herstellung von Salzen cyclischer Amidine
WO1999032446A1 (fr) * 1997-12-22 1999-07-01 Ajinomoto Co., Inc. Agent de conservation de fraicheur pour fleurs coupees
EP1043314A4 (fr) * 1997-12-22 2001-01-24 Ajinomoto Kk Nouveau derive de dihydropyridine
US6235759B1 (en) 1998-10-29 2001-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1A adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6232318B1 (en) 1998-11-12 2001-05-15 Merck & Co., Ltd. Pyrimidinedione derivatives useful as alpha 1A adrenoceptor antagonists
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US7247645B2 (en) 1999-06-23 2007-07-24 Ajinomoto Co., Inc. Dihydropyridine derivatives
US6436962B1 (en) 1999-09-30 2002-08-20 Merck & Co., Inc. Arylhydantoin derivatives and uses thereof
US6326372B1 (en) 1999-09-30 2001-12-04 Merck & Co., Inc. Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
US6316437B1 (en) 1999-09-30 2001-11-13 Merck & Co., Inc. Spirohydantoin compounds and uses thereof
US6387893B1 (en) 1999-09-30 2002-05-14 Merck & Co., Inc. Spirotricyclic substituted azacycloalkane derivatives and uses thereof
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
US7618959B2 (en) 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
WO2008052431A1 (fr) * 2006-10-25 2008-05-08 Beijing Huaanfo Biomedical Research Centre. Inc Utilisation d'une composition contenant de l'amlodipine dans la preparation de medicaments destines au traitement d'un trouble de la voie urinaire inferieure
US9296743B2 (en) 2008-01-11 2016-03-29 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9650378B2 (en) 2008-01-11 2017-05-16 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US12357639B2 (en) 2017-09-22 2025-07-15 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
US11426412B2 (en) 2017-10-18 2022-08-30 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CN109721596A (zh) * 2017-10-27 2019-05-07 广东东阳光药业有限公司 苯基取代的二氢吡啶类化合物及其用途
CN109721596B (zh) * 2017-10-27 2020-12-18 广东东阳光药业有限公司 苯基取代的二氢吡啶类化合物及其用途
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
US11459338B2 (en) 2017-11-24 2022-10-04 Jubilant Episcribe Llc Heterocyclic compounds as PRMT5 inhibitors
US11529341B2 (en) 2018-03-13 2022-12-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation

Also Published As

Publication number Publication date
IL109220A0 (en) 1994-07-31
WO1994022829A3 (fr) 1995-01-05
AU6498694A (en) 1994-10-24

Similar Documents

Publication Publication Date Title
WO1994022829A2 (fr) Dihydropyridines et leurs nouvelles utilisations
US5767131A (en) Dihydropyridines and new uses thereof
US5861392A (en) Therapeutic heterocycles
AU680457B2 (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
US5559131A (en) Carboxamide derivatives for treating asthma
CN1093858C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
JP2000506904A (ja) ジヒドロピリミジン類およびその使用
EA005289B1 (ru) Гетероциклические соединения, содержащие тетрагидропиридиновые или пиперидиновые группы, в качестве антагонистов рецепторов кортикотропин-рилизинг-фактора
KR19990063639A (ko) 파르네실 트랜스퍼라제 억제 기능을 갖는 2-퀴놀론 유도체
US5578611A (en) Use of α-1C specific compounds to treat benign prostatic hyperplasia
US6211198B1 (en) Dihydropyridines and new uses thereof
JP3676424B2 (ja) 複素環式化合物
WO1998038186A1 (fr) Quinoxalinediones
JP3114996B2 (ja) ヘテロ環式化合物及びそれを有効成分とする強心剤
AU6827998A (en) Quinoxalinediones
WO2000037026A1 (fr) Dihydropyrimidines et leurs utilisations
EP0991643B1 (fr) Nouveaux composes tricycliques aminooxyamide inhibiteurs de farnesyl-proteine transferase
WO2000006565A1 (fr) ANTAGONISTES DU RECEPTEUR ADRENERGIQUE ALPHA 1a
US20040138242A1 (en) Dihydropyrimidines and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 08211764

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA